Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NT-175 |
Synonyms | |
Therapy Description |
NT-175 comprises autologous T-lymphocytes engineered to express an HLA-A*02:01-restricted T-cell receptor (TCR) targeting TP53 R175H, and to lack expression of TGFBR2, which potentially induces a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing TP53 R175H and inhibits tumor growth (J Clin Oncol 2024 42:16_suppl, 5011, NCI Drug Dictionary). |